Pharmacology of the peptidomimetic, MEN 11149, a new potent, selective and orally effective tachykinin NK1 receptor antagonist

被引:14
作者
Cirillo, R
Astolfi, M
Conte, B
Lopez, G
Parlani, M
Terracciano, R
Fincham, CI
Manzini, S
机构
[1] Menarini Ric, Dept Pharmacol, I-00040 Pomezia, Italy
[2] Menarini Ric, Dept Chem, I-00040 Pomezia, Italy
关键词
tachykinin; tachykinin NK1 receptor antagonist; substance P;
D O I
10.1016/S0014-2999(97)01453-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In this study we investigated the pharmacological properties of MEN 11149, 2-(2-naphthyl)-1-N-{(1R,2S)-2-N-[1(H)indol-3-ylcarbonyl]aminocyclohexanecarbony}-1-[N'-methyl-N'-(4-methylphenylacetyl)]diaminoethane, a novel partially retro-inverse pseudo peptide antagonist of tachykinin NK1 receptors. MEN 11149 potently inhibits the binding of [H-3]substance P to tachykinin NK1 sites in IM9 cells (pK(i) = 8.5 +/- 0.1). The compound is highly specific for the human tachykinin NK1 receptors, since it has negligible effects (pK(i) < 6) on the binding of specific ligands to tachykinin NK2, NK3 receptors and a battery of central and peripheral receptors or ion channels. The tachykinin NK1 receptor antagonism of MEN 11149 appears to be insurmountable since, in saturation binding experiments, both K-D and B-max are significantly affected by incubation with the compound (1-30 nM). Ln isolated guinea-pig ileum, MEN 11149 (0.1-100 nM) shifts to the right in a non-parallel way the substance P methyl ester-induced cumulative concentration-response curve with progressive inhibition of the maximal response (pK(B) = 9.6 +/- 0.1). When tested for reversibility at 5 nM in the same preparation, the compound displays a slow dissociation rate compared to the fast dissociation rate with FK888 (N-2-[(4R)-4-hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl]-N-methyl-N-phenylmethyl-L-3-(2-naphthyl)alaninamide) at 5 nM. In the same preparation, MEN 11149 (10 mu M) did not affect the cumulative concentration-response curve to acetylcholine. In vivo, MEN 11149 dose dependently antagonizes [Sar(9),Met(O-2)(11)]substance P-induced bronchoconstriction in anaesthetized guinea-pigs (ID50 = 83 +/- 31 nmol/kg i.v.). The duration of the effect exceeds 3 h. MEN 11149 does not affect the bronchoconstriction induced by neurokinin A. The compound dose dependently inhibits [Sar(9),Met(O-2)(11)]substance P-induced plasma protein extravasation in guinea-pig bronchi whether administered intravenously (ID50 = 0.22 +/- 0.02 mu mol/kg) or orally (ID50 = 0.97 +/- 0.21 mu mol/kg). These results demonstrate that MEN 11149 is a potent, highly selective and orally effective insurmountable antagonist of tachykinin NK1 receptors with a long duration of action. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:201 / 209
页数:9
相关论文
共 35 条
  • [1] The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK1 receptor antagonist
    Beattie, DT
    Beresford, IJM
    Connor, HE
    Marshall, FH
    Hawcock, AB
    Hagan, RM
    Bowers, J
    Birch, PJ
    Ward, P
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (08) : 3149 - 3157
  • [2] RECENT DEVELOPMENTS IN TACHYKININ NK1 RECEPTOR ANTAGONISTS - PROSPECTS FOR THE TREATMENT OF MIGRAINE HEADACHE
    BEATTIE, DT
    CONNOR, HE
    HAGAN, RM
    [J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1995, 73 (07) : 871 - 877
  • [3] A water-soluble, stable dipeptide NK1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523
    Bonnet, J
    Kucharczyk, N
    Robineau, P
    Lonchampt, M
    Dacquet, C
    Regoli, D
    Fauchere, JL
    Canet, E
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1996, 310 (01) : 37 - 46
  • [4] ORGANIZATION OF SUBSTANCE-P PRIMARY SENSORY NEURONS - ULTRASTRUCTURAL AND PHYSIOLOGICAL CORRELATES
    CUELLO, AC
    RIBEIRODASILVA, A
    MA, W
    DE KONINCK, Y
    HENRY, JL
    [J]. REGULATORY PEPTIDES, 1993, 46 (1-2) : 155 - 164
  • [5] CP-96,345 ANTAGONISM OF NK(1) RECEPTORS AND SMOKE-INDUCED PROTEIN EXTRAVASATION IN RELATION TO ITS CARDIOVASCULAR EFFECTS
    DELAYGOYET, P
    FRANCOCERECEDA, A
    GONSALVES, SF
    CLINGAN, CA
    LOWE, JA
    LUNDBERG, JM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1992, 222 (2-3) : 213 - 218
  • [6] BMS-180560, AN INSURMOUNTABLE INHIBITOR OF ANGIOTENSIN II-STIMULATED RESPONSES - COMPARISON WITH LOSARTAN AND EXP3174
    DICKINSON, KEJ
    COHEN, RB
    SKWISH, S
    DELANEY, CL
    SERAFINO, RP
    POSS, MA
    GU, Z
    RYONO, DE
    MORELAND, S
    POWELL, JR
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (01) : 179 - 189
  • [7] IN-VITRO AND IN-VIVO BIOLOGICAL-ACTIVITIES OF SR140333, A NOVEL POTENT NONPEPTIDE TACHYKININ NK1, RECEPTOR ANTAGONIST
    EMONDSALT, X
    DOUTREMEPUICH, JD
    HEAULME, M
    NELIAT, G
    SANTUCCI, V
    STEINBERG, R
    VILAIN, P
    BICHON, D
    DUCOUX, JP
    PROIETTO, V
    VANBROECK, D
    SOUBRIE, P
    LEFUR, G
    BRELIERE, JC
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 250 (03) : 403 - 413
  • [8] PHARMACOLOGICAL PROFILE OF A HIGH-AFFINITY DIPEPTIDE NK1-RECEPTOR ANTAGONIST, FK888
    FUJII, T
    MURAI, M
    MORIMOTO, H
    MAEDA, Y
    YAMAOKA, M
    HAGIWARA, D
    MIYAKE, H
    IKARI, N
    MATSUO, M
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1992, 107 (03) : 785 - 789
  • [9] Gardner CJ, 1996, BRIT J PHARMACOL, V118, pP78
  • [10] GITTER BD, 1995, J PHARMACOL EXP THER, V275, P737